Biomarker Deep-Dive: DHEA-S

Dehydroepiandrosterone sulfate — DHEA-S — is the most abundant circulating steroid hormone in the human body. Yet it remains one of the most underappreciated biomarkers in routine clinical practice. Produced almost exclusively by the zona reticularis of the adrenal cortex, DHEA-S serves as the body's primary reservoir for sex hormone synthesis and carries a physiological footprint that extends well beyond its role as a hormonal precursor: it modulates immune function, supports neurological integrity, influences insulin sensitivity, and mirrors the pace of biological aging with remarkable consistency.

Perhaps most strikingly, DHEA-S undergoes one of the most dramatic age-related declines of any hormone — falling 80–95% between the ages of 25 and 80. This trajectory, known as adrenopause, is independent of sex and begins as early as the late twenties. The epidemiological consequences are well-documented: low DHEA-S has been associated with increased all-cause mortality, cardiovascular disease, cognitive decline, and metabolic dysfunction across multiple large prospective cohorts.

This article examines the biology of DHEA-S from synthesis to cellular action, its clinical relevance across metabolic health, athletic performance, and longevity, and the measurement considerations that make it a particularly robust and reliable biomarker for longitudinal tracking.

1. What Is DHEA-S?

DHEA-S (molecular formula C₁₉H₂₈O₅S) is the 3β-sulfate ester of dehydroepiandrosterone (DHEA). The sulfate group conjugated at the C3β-hydroxyl position makes DHEA-S hydrophilic, which is the key to understanding its clinical utility. This structural difference from DHEA has profound implications for how the two molecules behave in circulation.

Whereas DHEA has a half-life of only 15–30 minutes and follows a pronounced cortisol-like circadian rhythm, DHEA-S circulates with a half-life of 7–10 hours, maintains stable concentrations throughout the day, and reaches serum levels approximately 250–500 times higher than DHEA. DHEA-S does not bind to sex hormone-binding globulin (SHBG), circulating instead loosely bound to albumin. These properties — long half-life, minimal diurnal variation, high concentration, and pre-analytical stability — collectively make DHEA-S the preferred clinical biomarker over DHEA itself.

DHEA-S is hormonally inert at nuclear steroid receptors but functions as a stable circulating reservoir. Peripheral tissues convert it back to DHEA via steroid sulfatase (STS), and from there into androgens and estrogens through the intracrine pathway — meaning sex steroid production happens inside target tissues, not in the endocrine glands.

2. Biosynthesis: The Adrenal Steroidogenic Pathway

DHEA-S production follows the Δ5 steroidogenic pathway through four enzymatic steps, almost exclusively in the adrenal zona reticularis:

• Cholesterol → Pregnenolone: Catalyzed by CYP11A1 (P450 side-chain cleavage enzyme) in the mitochondria. The StAR protein controls cholesterol transport across the mitochondrial membrane — the true rate-limiting step of all steroidogenesis.
  
  
• Pregnenolone → DHEA: A two-step reaction catalyzed by CYP17A1 (17α-hydroxylase/17,20-lyase). The lyase activity critically depends on cytochrome b5 (CYB5A), which enhances efficiency approximately 10-fold through allosteric interaction. This Δ5 pathway is roughly 100 times more efficient than the Δ4 route for DHEA production.
  
  
• DHEA → DHEA-S: Sulfation by SULT2A1 using PAPS (3′-phosphoadenosine 5′-phosphosulfate) as the sulfate donor. Recent evidence suggests that SULT2A1 physically associates with CYP17A1 and CYB5A in a multienzyme complex, enabling direct metabolic channeling from DHEA synthesis to DHEA-S formation.
  
  
• DHEA-S → DHEA (peripheral reconversion): Steroid sulfatase (STS) desulfates DHEA-S back to bioactive DHEA within target tissues — the entry point to local sex steroid synthesis.

The zona reticularis is uniquely equipped for DHEA-S production because it strongly expresses CYB5A and SULT2A1 while minimally expressing HSD3B2, which would otherwise divert pregnenolone toward cortisol. ACTH is the primary upstream regulator via the HPA axis, with IGF-I and IGF-II providing additional stimulatory input on CYP17A1 expression.

3. Physiological Roles: Beyond Hormonal Precursor

Intracrine Sex Hormone Production

DHEA-S is the master upstream precursor for peripheral sex steroid synthesis. In premenopausal women, 50–75% of estrogens and the majority of androgens are derived from intracrine DHEA metabolism in tissues. After menopause, this proportion rises to over 90% for both estrogens and androgens. In older men, more than half of circulating androgens originate from adrenal precursors including DHEA-S — a fact that underscores why DHEA-S monitoring is relevant regardless of sex.

Metabolic Function

DHEA-S influences metabolism through multiple parallel pathways. It activates PPARα, regulating lipid oxidation, glucose homeostasis, and apoptosis. In the liver and skeletal muscle, DHEA enhances glucose uptake by inducing GLUT1 and GLUT4 translocation to the plasma membrane via PI3-kinase/Akt and AMPK-PGC-1α-NRF-1 signaling. Epidemiological data consistently associate low DHEA-S with visceral fat accumulation, dyslipidemia, and accelerated atherosclerosis progression.

Immune Modulation

DHEA-S functionally counterbalances cortisol's immunosuppressive effects. It modulates Th1/Th2 balance, inhibits the pro-inflammatory cytokines TNF-α and IL-6, and supports T-cell and monocyte function. This dynamic interaction with the glucocorticoid system is why the cortisol:DHEA-S ratio has emerged as a key composite metric of immune competence and HPA axis balance — arguably more informative than either hormone measured in isolation.

Neuroprotection

DHEA-S is an active neurosteroid with several distinct mechanisms of action in the central nervous system. It acts as a negative allosteric modulator of GABA-A receptors (reducing inhibitory tone and promoting neural plasticity) and a positive allosteric modulator of NMDA receptors (enhancing excitatory glutamatergic signaling and long-term potentiation). It directly binds TrkA and p75NTR neurotrophin receptors with high affinity (~5 nM), functioning as an endogenous neurotrophic factor that stimulates neurite outgrowth and prevents neuronal apoptosis. Clinical data associate lower DHEA-S concentrations with greater cognitive decline, reduced executive function, and higher dementia risk in older adults.

Cardiovascular Biology

DHEA activates endothelial nitric oxide synthase (eNOS), promoting nitric oxide release and vasodilation. It inhibits vascular inflammation through PPARα activation and NF-κB suppression. Epidemiological data from several large cohort studies suggest that men with the lowest DHEA-S levels were approximately 67% more likely to die from myocardial infarction and 54% more likely to die from any cause, compared to those with the highest levels.

4. Adrenopause: The Lifelong Trajectory of DHEA-S

DHEA-S follows a developmental arc unlike any other hormone. Concentrations are high during fetal life (driven by the fetal adrenal's role in placental estrogen synthesis), drop sharply after birth, remain low through early childhood, rise dramatically at adrenarche (ages 6–8), peak in the mid-twenties, and then decline at approximately 2–5% per year from the late twenties onward — without stopping.

By the time of menopause, circulating DHEA-S has typically fallen 60% below peak. By ages 70–80, only 10–20% of peak values remain. In nonagenarians and centenarians, declines can reach 95%. Critically, cortisol production remains stable or even increases slightly over the same period — creating a progressive relative glucocorticoid excess that amplifies immunosenescence, sarcopenia, and metabolic dysfunction. This shift in the cortisol:DHEA-S balance is a defining feature of physiological aging, and its measurement offers a practical clinical window into that process.

The mechanism behind adrenopause involves decreased 17,20-lyase activity of CYP17A1, reduction in the mass of the zona reticularis, and declining IGF-I and IGF-II support for adrenal steroidogenesis. This decline occurs independently of sex and independently of menopause — it is a universal phenomenon that begins in early adulthood.

5. Clinical Relevance Across Key Domains

Metabolic Health and Nutrition

Low DHEA-S is associated with all components of metabolic syndrome. Epidemiological data from the Rancho Bernardo Study documented an inverse relationship between DHEA-S and systolic blood pressure, fasting glucose, 2-hour glucose, and triglycerides. The cortisol:DHEA-S ratio increases approximately 3-fold across the 40-year span from age 50 to 89, as DHEA-S declines ~60% while cortisol rises ~10%.

The Vietnam Experience Study (4,255 veterans) found that an increasing cortisol:DHEA-S ratio independently predicted incident metabolic syndrome and each of its four major components. In a randomized controlled trial (Villareal and Holloszy, JAMA 2004), 50 mg/day DHEA for six months reduced visceral fat by 13 cm² versus a +3 cm² increase in the placebo group (P=0.001), alongside significant improvements in insulin sensitivity.

DHEA's metabolic effects are mediated through AMPK-PGC-1α-NRF-1 signaling and activation of the IRS1-AKT-GLUT2 pathway in the liver, offering both anti-steatotic and insulin-sensitizing effects in high-fat-feeding animal models. A 2-year DHEA replacement study in elderly humans demonstrated an 18–21 mg/dL reduction in 2-hour glucose and approximately a 22% reduction in the insulin resistance product.

For individuals tracking nutritional biomarkers, DHEA-S contextualizes findings around cortisol, insulin, and metabolic hormones — and helps distinguish whether metabolic dysfunction may have an adrenal or stress-mediated component.

Sport Performance and Recovery

In athletic contexts, DHEA-S provides a window into adrenal reserve and training adaptation. Acute exercise transiently elevates both cortisol and DHEA-S, but their relative balance over time tells a more nuanced story. Resistance training tends to produce stronger DHEA-S responses than endurance training. Notably, sixteen weeks of regular structured exercise has been associated with an approximately 30% reduction in the cortisol:DHEA-S ratio, reflecting improved adrenal hormonal balance.

Overtraining syndrome (OTS) progression follows a characteristic three-stage hormonal trajectory:

• Stage I: Elevated cortisol, normal DHEA-S — acute, transient stress response
  
• Stage II: Elevated cortisol, declining DHEA-S — loss of anabolic buffering; the cortisol:DHEA-S ratio begins to rise
  
• Stage III: Low cortisol, low DHEA-S — adrenal exhaustion, marked fatigue, impaired recovery, elevated injury and illness risk

The cortisol:DHEA-S ratio and the testosterone:cortisol ratio are complementary surveillance metrics in sport science; when both decline simultaneously, maladaptive training stress is likely. Serial DHEA-S monitoring across a training season — particularly when combined with Ferritin and inflammatory markers — may provide an earlier signal of overreaching than subjective fatigue scales alone.

It is important to note that DHEA is classified under WADA category S1 (Anabolic Agents) and is prohibited in all competitive sports at all times. It is the most frequently detected prohibited anabolic agent in commercially available dietary supplements. Athletes should approach any supplementation discussion with appropriate regulatory awareness.

Longevity and All-Cause Mortality

The longevity literature on DHEA-S is among the most consistent in endocrinology. A meta-analysis of six prospective cohort studies found that the lowest DHEA-S categories were associated with a pooled relative risk of 1.46 (95% CI: 1.25–1.70) for all-cause mortality in elderly populations. The Tanushimaru Study, with a 27-year follow-up, found that each 100 μg/dL increase in DHEA-S was associated with a 36% reduced risk of death from any cause in men. The MrOS Sweden study (2,644 men) found low DHEA-S predicted cardiovascular death (HR 1.61) and ischemic heart disease death (HR 1.67), independent of traditional cardiovascular risk factors.

Among centenarians, those with the highest functional status tended to maintain the highest DHEA-S levels. The WISE study in 270 postmenopausal women showed that the lowest DHEA-S tertile carried a 2.55-fold greater cardiovascular mortality risk.

A 2025 study using the Midlife in the United States cohort (969 individuals) found that the cortisol:DHEA-S ratio was the single strongest predictor of epigenetic age acceleration, outperforming either hormone measured alone — with the strongest effects on the Hannum and PhenoAge epigenetic clocks. This finding connects DHEA-S not merely to crude survival statistics but to the biology of aging at the cellular level.

It is worth noting that while the association between low DHEA-S and mortality is consistently observed in men, evidence in women is more nuanced — some studies point toward a U-shaped relationship where both very low and very high DHEA-S carry greater risk. Furthermore, the trajectory of DHEA-S decline over time may be more predictive than any single measurement, with steeper decline trajectories associated with up to 75% greater mortality risk. This underscores the value of serial, longitudinal tracking rather than single-point assessment.

For a broader view of biomarkers relevant to aging trajectories, see Biostarks' overview of top biomarkers for longevity.

6. Biomarker Interpretation: Reference Ranges and Context

DHEA-S reference ranges are strongly age- and sex-dependent. The following are approximate clinical reference ranges expressed in μg/dL:

Females:

• 18–29 years: 45–320 μg/dL
  
• 30–39 years: 40–325 μg/dL
  
• 40–49 years: 25–220 μg/dL
  
• 50–59 years: 15–170 μg/dL
  
• 60+ years: <145 μg/dL

Males:

• 18–29 years: 110–510 μg/dL
•  30–39 years: 110–370 μg/dL
  
• 40–49 years: 45–345 μg/dL
  
• 50–59 years: 25–240 μg/dL
  
• 60+ years: <204 μg/dL

Conversion: μg/dL × 0.02714 = μmol/L. Reference ranges vary by assay platform and laboratory.

Elevated DHEA-S may suggest:

• Polycystic ovary syndrome (PCOS) — present in 20–30% of affected women even when other androgens are normal
  
• Androgen-secreting adrenal tumor (values >600 μg/dL warrant investigation)
  
• Congenital adrenal hyperplasia (often 5–10-fold elevations in 21-hydroxylase deficiency)
  
• ACTH-dependent Cushing's disease
  
• Premature adrenarche in children

Low DHEA-S may suggest:

• Normal aging (the most common cause in adults over 40)
  
• Primary or secondary adrenal insufficiency
  
• Hypopituitarism
  
• HPA axis dysregulation associated with chronic stress or burnout
  
• Cortisol-producing adrenal adenoma — found in 87.5% of such cases due to ACTH suppression
  
• Chronic systemic disease (cardiovascular disease, type 2 diabetes, systemic inflammation)

Key confounding factors

• Corticosteroids: Exogenous glucocorticoids suppress ACTH, directly reducing adrenal DHEA-S output
  
  
• Statins: A meta-analysis of 10 RCTs showed statins significantly reduce DHEA-S (SMD: −0.43, P=0.02), with atorvastatin having the strongest effect
  
  
• BMI and insulin: Hyperinsulinemia may directly suppress adrenal DHEA-S production in a bidirectional relationship
  
  
• Genetics: SNP rs6162 in CYP17A1 accounts for up to 20% of inter-individual variation; rs2637125 in SULT2A1 is associated with low circulating DHEA-S
  
  
• Smoking: Smokers with low DHEA-S show dramatically elevated mortality risk in some cohort data

Single-point DHEA-S values are most informative when interpreted alongside age, sex, cortisol, and clinical context. Trends over time — obtained through repeat testing — are generally more meaningful than isolated measurements.

7. Biomarker Mapping: DHEA-S and Its Measurement Ecosystem

DHEA-S does not function in isolation. Interpreting it within a broader hormonal and metabolic panel significantly increases its clinical signal:

• Cortisol → cortisol:DHEA-S ratio: The single most informative ratio for HPA axis balance, stress resilience, immune competence, and epigenetic age acceleration. Measurement: automated immunoassay (serum cortisol) or LC-MS/MS for high-precision work.
  
  
• Total and free testosterone: DHEA-S is the dominant precursor for peripheral testosterone, especially in women and older men. Testosterone and DHEA-S should be interpreted together in any hormonal evaluation.
  
  
• SHBG: DHEA supplementation has been shown to reduce SHBG by up to 40% in women, increasing bioavailable sex steroids — an important interaction when interpreting free hormone fractions.
  
  
• IGF-1: Both DHEA-S and IGF-1 decline in parallel with aging (somatopause and adrenopause), and their combined decline may synergistically drive sarcopenia and functional decline.
  
  
• Insulin / HOMA-IR: DHEA-S and insulin sensitivity are bidirectionally linked; metabolic panels are meaningfully enriched by DHEA-S inclusion.
  
  
• Estradiol: In postmenopausal women, estradiol is virtually entirely derived from DHEA-S via peripheral aromatization — making DHEA-S an important upstream variable in any hormonal interpretation post-menopause.

8. Analytical Measurement: Why LC-MS/MS Sets the Standard

DHEA-S can be measured by automated immunoassay or by liquid chromatography-tandem mass spectrometry (LC-MS/MS). The latter is considered the gold standard:

• Immunoassays (ELISA, CLIA) are widely available and fast but may cross-react with structurally similar steroids. Comparative studies have documented significant positive bias versus LC-MS/MS in some populations, particularly where interfering compounds are elevated (e.g., pregnancy-related steroids).
  
• LC-MS/MS offers superior specificity, allowing simultaneous multi-steroid profiling with linearity to 15 μmol/L, mean bias below 1%, and functional sensitivity of 0.1 μmol/L. The tradeoff is greater cost and longer turnaround.

Unlike cortisol — which must be collected at a specific time of day to account for diurnal variation — DHEA-S requires no fasting and no specific timing. This pre-analytical simplicity makes it well-suited for routine monitoring, finger-prick dried blood collection, and at-home testing workflows.

For a practical discussion of how analytical platform choices affect biomarker result reliability, see Biostarks' article on best practices for biomarker analysis.

9. How Biostarks Can Help

DHEA-S alone is a powerful signal. But its full clinical value emerges when placed within the context of cortisol balance, sex hormone production, metabolic function, and inflammatory status. Biostarks panels are built around this multi-biomarker logic — allowing DHEA-S to be interpreted not in isolation, but as part of a coherent, integrated biological picture.

•  
• Metabolic Health Panel — tracks insulin sensitivity, hormonal balance, and cardiometabolic risk markers
•  
• Nutrition Panel — assesses nutritional sufficiency and key metabolic hormones relevant to energy and body composition
•  
• Sport Performance Panel — coming late summer 2026

Whether the goal is understanding a plateau in body composition, assessing recovery capacity between training blocks, or tracking the hormonal trajectory of biological aging, DHEA-S measurement provides a window that few other single biomarkers can match.

References

• A prospective study of dehydroepiandrosterone sulfate, mortality, and cardiovascular disease — New England Journal of Medicine — Barrett-Connor E, Khaw KT, Yen SS — (1986) — Source
  
• Low serum levels of dehydroepiandrosterone sulfate predict all-cause and cardiovascular mortality in elderly Swedish men — Journal of Clinical Endocrinology & Metabolism — Ohlsson C, Labrie F, Barrett-Connor E, et al. — (2010) — Source
  
• DHEA-S levels and cardiovascular disease mortality in postmenopausal women: results from the WISE Study — Journal of Clinical Endocrinology & Metabolism — Shufelt C et al. — (2010) — Source
  
• Effect of DHEA on abdominal fat and insulin action in elderly women and men: a randomized controlled trial — JAMA — Villareal DT, Holloszy JO — (2004) — Source
  
• DHEA in elderly women and DHEA or testosterone in elderly men — New England Journal of Medicine — Nair KS, Rizza RA, O'Brien P, et al. — (2006) — Source
  
• Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: contribution of the DHEAge Study to a sociobiomedical issue — PNAS — Baulieu EE, Thomas G, Legrain S, et al. — (2000) — Source
  
• Cortisol, DHEA sulphate, their ratio, and all-cause and cause-specific mortality in the Vietnam Experience Study — European Journal of Endocrinology — Phillips AC, Carroll D, et al. — (2010) — Source
  
• Cortisol, DHEAS, and the cortisol/DHEAS ratio as predictors of epigenetic age acceleration — PMC — (2025) — Source
  
• Neurobiological and neuropsychiatric effects of dehydroepiandrosterone (DHEA) and DHEA sulfate (DHEAS) — Frontiers in Neuroendocrinology — Maninger N, Wolkowitz OM, Reus VI, et al. — (2009) — Source
  
• Adrenal Androgens and Aging — Endotext, NCBI Bookshelf — Rainey WE, Nakamura Y — Source
  
• A review of age-related dehydroepiandrosterone decline and its association with well-known geriatric syndromes: is treatment beneficial? — PMC — (2013) — Source
  
• Hormonal aspects of overtraining syndrome: a systematic review — BMC Sports Science, Medicine and Rehabilitation — Cadegiani FA, Kater CE — (2017) — Source